Abstracts tagged "complement"

Abstract Number: 2171 • 2014 ACR/ARHP Annual Meeting
Polymorphisms in theÂ FCN1Â Gene Coding for M-Ficolin Are Associated with Disease Activity, Radiographic Damage and Are the Strongest Predictors of DAS28 Remission in 180 DMARD naÃ¯ve Early Rheumatoid Arthritis Patients
Christian G. Ammitzbøll¹, Rudi Steffensen², Steffen Thiel³, Jens Christian Jensenius³, Kim Horslev-Petersen⁴, Torkell Ellingsen^5,6, Merete Lund Hetland⁷, Peter Junker⁸, Mikkel Ostergaard⁹ and Kristian Stengaard-Pedersen¹⁰, ¹Arhus University Hospital, Aarhus, Denmark, ²Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark, ³Biomedicine, Aarhus University, Aarhus, Denmark, ⁴Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Graasten, Denmark, ⁵Reumatology, Odense University Hospital, Odense, Denmark, ⁶Diagnostic Center, Regional Hospital Silkeborg, Silkeborg, Denmark, ⁷DANBIO, Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Dept of Rheumatology RM, Copenhagen University Hospital, Glostrup, Denmark, ¹⁰Rheumatology, Arhus University Hospital, Aarhus, Denmark
Background/Purpose: M-ficolin is a pattern recognition molecule that collaborates with associated serine proteases as an activator of the complement system. High M-ficolin levels are strongly…
Abstract Number: 1924 • 2014 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus
Rosalind Ramsey-Goldman¹, Richard Furie², Chaim Putterman³, Anka Askanase⁴, Jill P. Buyon⁵, Kenneth Kalunian⁶, W. Winn Chatham⁷, E Massarotti⁸, Kyriakos A. Kirou⁹, A. Weinstein¹⁰, Puja Chitkara¹¹, Susan Manzi¹², Joe Ahearn¹³, Leilani Wolover¹⁴, John Conklin¹⁵, Tyler O'Malley¹⁴, Claudia Ibarra¹⁵, Derren Barken¹⁶ and Thierry Dervieux¹⁷, ¹FSM-300, Northwestern University, Chicago, IL, ²Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ³The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Department of Medicine Rhemuatology, Colombia University, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶UCSD School of Medicine, La Jolla, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Washington Hospital Center, Washington, DC, ¹¹Internal Medicine, Sharp Memorial Hospital, San Diego, CA, ¹²Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹³Internal Medicine, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁴Research and Development, Exagen Diagnostics, Inc., Vista, CA, ¹⁵1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ¹⁶Exagen Diagnostics, Inc., Vista, CA, ¹⁷rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Elevated levels of cell bound complement activation products (CBCAPS) have been established as valuable biomarkers in the diagnosis of Systemic Lupus Erythematosus (SLE). In…
Abstract Number: 1649 • 2014 ACR/ARHP Annual Meeting
High Specificity of Skin Immunoglobulin Deposits for diagnosing SLE in Patients with Lupus Nephritis
Marco Ulises Martinez-Martinez¹, Maria Daniela De Avila², Mario Perales³, Lourdes Baranda⁴, Susana Román Acosta⁵, Jaime Antonio Borjas García⁵ and Carlos Abud-Mendoza¹, ¹Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ²Regional Unit Rheumatology and Osteoporosis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ³Regional Unit of Rheumatology and Osteoporosis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁴Regional Unit of Rheumatology and Osteoposis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁵Nephrology Department, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
Background/Purpose: Deposit of different classes of immunoglobulins is the main feature of lupus nephritis;1 because of its high specificity, a patient is classified as having…
Abstract Number: 1200 • 2014 ACR/ARHP Annual Meeting
Plasma Levels of Pattern Recognition Molecules of the Lectin Pathway Are Altered in SLE Patients
Anne Troldborg^1,2, Steffen Thiel³, Magdalena Janina Laska³, Bent Deleuran^4,5, Jens Christian Jensenius³ and Kristian Stengaard-Pedersen^2,6, ¹clinical medicine, Aarhus University, Aarhus, Denmark, ²Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Biomedicine, Aarhus University, Aarhus, Denmark, ⁴Department of Biomedicine, Aarhus University, Aarhus, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Clinical medicine, Aarhus University, Aarhus, Denmark
Background/Purpose Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease where the Complement System plays a key role in the pathogenesis. The objective of this…
Abstract Number: 2892 • 2013 ACR/ARHP Annual Meeting
Masp-1/3 Deficient MRL/Lpr Mice Lack The Alternative Complement Pathway Activation and Are Protected From Development Of Lupus-Like Glomerulonephritis
Takeshi Machida¹, Natsumi Sakamoto¹, Teizo Fujita¹, Minoru Takahashi² and Hideharu Sekine¹, ¹Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Department of Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan
Background/Purpose: Complement has both protective and pathogenic functions in lupus due to a balance between its role in the clearance of immune complexes (ICs) and…
Abstract Number: 2703 • 2013 ACR/ARHP Annual Meeting
An Intronic CR2 Polymorphism Associated With Systemic Lupus Erythematosus Alters CTCF Binding and CR1 Expression
Jian Zhao¹, Brendan M. Giles², Rhonda L. Taylor³, Gabriel A. Yette², Kara M. Lough², Lawrence J. Abraham³, Hui Wu⁴, Patrick M. Gaffney⁵, Jennifer A. Kelly⁶, Kenneth M. Kaufman^7,8, John B. Harley^9,10, Carl D. Langefeld¹¹, Elizabeth E. Brown¹², Jeffrey C. Edberg¹³, Robert P. Kimberly¹⁴, Daniela Ulgiati³, Betty P. Tsao¹ and Susan A. Boackle¹⁵, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²University of Colorado School of Medicine, Aurora, CO, ³University of Western Australia, Perth, Western Australia, Australia, ⁴Rheumatology, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷U.S. Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹²University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁴Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁵Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by the production of antibodies to nuclear antigens, which form immune complexes that deposit in tissues and cause…
Abstract Number: 1865 • 2013 ACR/ARHP Annual Meeting
Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies
Edward Bernton¹, Antonio Polley², Susan Zondlo², Lynne Mitchell³ and Dennis Hourcade³, ¹Protalex Inc., Summit, NJ, ²QPS Holdings LLC, Newark, DE, ³Division of Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: PRTX-100, a highly-purified GMP staphylococcal protein A (SpA), is currently in clinical trials treating patients with active rheumatoid arthritis (RA). It has been reported…
Abstract Number: 1765 • 2013 ACR/ARHP Annual Meeting
Complement Component C5a Permits The Co-Existence Of Pathogenic Th17 Cells and Type I Interferon In Lupus
Marc C. Levesque¹, Sudesh Pawaria², Kelly Maers² and Partha Biswas³, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Dept. of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a type I interferon (IFN-I)-driven autoimmune disorder with exaggerated B and T-helper (Th) cell responses. Th17 cells, a recently…
Abstract Number: 542 • 2013 ACR/ARHP Annual Meeting
Evidence For Involvement Of C5a Receptor in Human and Murine Lupus Nephritis
Constanze Hess¹, Ditte Tornehave², Peter Helding Kvist², Yvonne Sundström³, Louise Berg³, Iva Gunnarsson⁴, Søren Jacobsen⁵, Claus Haase¹ and Lars Hornum¹, ¹Department of Immunopharmacology, Novo Nordisk A/S, Måløv, Denmark, ²Department of Histology, Novo Nordisk A/S, Måløv, Denmark, ³Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Background/Purpose: The complement system plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Apart from the activation of the early components of…
Abstract Number: 20 • 2013 ACR/ARHP Annual Meeting
Complement Deposition On Platelets Is Associated To Venous Thrombosis In Systemic Lupus Erythematosus
Christian Lood¹, Helena Tydén¹, Birgitta Gullstrand², Gunnar Sturfelt³, Andreas Jönsen¹, Lennart Truedsson² and Anders A. Bengtsson¹, ¹Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: Anti-phospholipid (aPL) antibodies are associated with development of venous thrombosis and stroke in the autoimmune disease systemic lupus erythematosus (SLE). The underlying mechanism for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].